610 related articles for article (PubMed ID: 11757504)
1. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Brown BG; Zhao XQ; Chait A; Fisher LD; Cheung MC; Morse JS; Dowdy AA; Marino EK; Bolson EL; Alaupovic P; Frohlich J; Albers JJ
N Engl J Med; 2001 Nov; 345(22):1583-92. PubMed ID: 11757504
[TBL] [Abstract][Full Text] [Related]
2. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.
Cheung MC; Zhao XQ; Chait A; Albers JJ; Brown BG
Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1320-6. PubMed ID: 11498460
[TBL] [Abstract][Full Text] [Related]
4. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
[TBL] [Abstract][Full Text] [Related]
5. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
[TBL] [Abstract][Full Text] [Related]
6. Antioxidant versus lipid-altering therapy--some answers, more questions.
Freedman JE
N Engl J Med; 2001 Nov; 345(22):1636-7. PubMed ID: 11757512
[No Abstract] [Full Text] [Related]
7. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
8. The effects of simvastatin-niacin and antioxidant therapy on HDL.
Drown DJ
Prog Cardiovasc Nurs; 2002; 17(2):102-3. PubMed ID: 11986546
[No Abstract] [Full Text] [Related]
9. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
10. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
12. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
13. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Asztalos BF; Batista M; Horvath KV; Cox CE; Dallal GE; Morse JS; Brown GB; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):847-52. PubMed ID: 12637338
[TBL] [Abstract][Full Text] [Related]
14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
17. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Robinson JG
Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
[TBL] [Abstract][Full Text] [Related]
18. High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
Singh U; Otvos J; Dasgupta A; de Lemos JA; Devaraj S; Jialal I
Clin Chem; 2007 Mar; 53(3):525-8. PubMed ID: 17234730
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Kris-Etherton PM
Curr Atheroscler Rep; 2001 Nov; 3(6):435-6. PubMed ID: 11602062
[No Abstract] [Full Text] [Related]
20. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]